SAN DIEGO—On April 17, 2020, the groundbreaking ceremony for BioDuro’s China Innovative Drug R&D Center was held in Wuxi Huishan Life Science Park in Jiangsu, China. The site is BioDuro’s 4th global facility, and 3rd in China. Upon completion, the facility will add another 300,000 ft2 and 1,000 scientists to BioDuro’s contract research, development and manufacturing operations.

David Preston, the chairman of BioDuro, said he was encouraged by the effectiveness and capability of controlling the novel coronavirus in China. After the operations begin, it will bring more than 1,000 high-end scientific research positions, provide more job opportunities for the local area, and contribute to the development of Wuxi City and Jiangsu biomedical industries.

TJ Deng, president of BioDuro, shared that BioDuro looked at 18 different cities, and the final selection is Wuxi Huishan Life Science Park. There is not only a huge market, but also a firm industrial mission and determination. The completion of the new BioDuro novel drug R&D center will attract more high-end talent to the region and promote the implementation of many more innovative drug research and development projects.

The BioDuro team were joined by government and industry leaders, including Wenbin Cao, a member of the standing committee of the Political Bureau of the CPC Central Committee. Mr. Cao highly affirmed BioDuro’s achievements and status in the field of new drug research and development CRO in his speech and expressed full confidence that the project will be completed promptly and put into operation as scheduled.

Wenbin Cao, Member of the Standing Committee of the Huishan District Committee and Director of the Management Committee of the Huishan Economic Development Zone said, "BioDuro is building the world’s largest R&D and production base in Huishan, and every level of government in the city of Wuxi will provide all aspects of service guarantee to ensure that the R&D center project is completed on time. We believe that the successful completion of the BioDuro project will accelerate the self-renewal of industrial technology and iterative upgrade of regional industries. This will boost Huishan’s life science and technological industrial chain, helping the city of Wuxi become a leading domestic, internationally renowned, and highly distinctive leader!"

BioDuro reached agreement with Huishan Life Science and Technology Park in October 2019, following a comprehensive search, selecting the project site from more than 18 other cities. Shortly thereafter, the COVID-19 pandemic created global health and business challenges. Despite these challenges, BioDuro and the Wuxi government worked tireless at all levels to ensure the project started smoothly. The facility is set to begin operations in August 2020.

Additional video of the groundbreaking ceremony can be found at:

Additional Media coverage can be found at:

BioDuro-Sundia, an Advent International portfolio company, is a leading global life sciences research and development organization that provides biopharmaceutical clients and partners with comprehensive, fully integrated drug discovery and development services, from lead development and IND-enabling studies to GMP manufacture of drug product for clinical trials. Core expertise includes small and large molecule discovery, development and scale up, combined with unique technology platforms such as bioavailability enhancement of insoluble compounds. The company has 4 global sites: headquarters in San Diego, California and 3 major operations in Beijing, Shanghai and Jiangsu, China. BioDuro’s integrated China and US teams afford partners with the benefits of a truly global and seamless operation, significantly accelerating discovery and de-risking development to create higher value outcomes.

For more information, visit: www.bioduro.com

SOURCE: BioDuro